• 1
    Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok ASF. Management of Hepatitis B: Summary of a Clinical Research Workshop. HEPATOLOGY 2007; 45: 10561075.
  • 2
    Eriksson S, Wang L. The role of cellular deoxynucleoside kinases in the activation of nucleoside analogs used in chemotherapy. Recent Advances in Nucelosides: Chemistry and Chemotherapy, ChuC.K. ed. Amsterdam: Elsevier, 2002: 455475.
  • 3
    Hulgan T, Haas DW. Toward a pharmacogenetic understanding of nucleotide and nucleoside analogue toxicity. J Infect Dis 2006; 194: 14711474.
  • 4
    Schildgen O, Sirma H, Funk A, Olotu C, Wend UC, Hartmann H, et al. Variant of hepatitis B virus with primary resistance to adefovir. N Engl J Med 2006; 354: 18071812.
  • 5
    Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 808816.
  • 6
    Yuen MF, Sablon E, Hui CH, Yuan HJ, Decraemer H, Laib CL. Factors preceding hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. HEPATOLOGY 34: 785791 2001: 785-791.
  • 7
    Lai CL, Leung N, Teo EK, Tong M, Wong F, Hann HW, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005; 129: 528536.
  • 8
    Locarnini S, Qi X, Arterburn S, Snow A, Brosgart CL, Currie G, et al. Incidence and predictors of emergence of Adefovir resistant HBV during four years of adefovir dipivoxil (ADV) therapy for patients with chronic hepatitis B (CHB) [Abstract]. J Hepatol 2005; 42: 17.
  • 9
    Ogata N, Fujii K, Takigawa S, Nomoto M, Ichida T, Asakura H. Novel patterns of amino acid mutations in the hepatitis B virus polymerase in association with resistance to lamivudine therapy in japanese patients with chronic hepatitis B. J Med Virol 1999; 59: 270276.
  • 10
    Locarnini S, Hatzakis A, Heathcote J, Keeffe EB, Liang TJ, Mutimer D, Pawlotsky JM, et al. Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther 2004; 9: 679693.
  • 11
    Zhou T, Saputelli J, Aldrich CE, Deslauriers M, Condreay LD, Mason WS. Emergence of drug-resistant populations of woodchuck hepatitis virus in woodchucks treated with the antiviral nucleoside lamivudine. Antimicrob Agents Chemother 1999; 43: 19471954.
  • 12
    Ono SK, Kato N, Shiratori Y, Kato J, Goto T, Schinazi RF, et al. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Invest 2001; 107: 449455.
  • 13
    Nafa S, Ahmed S, Tavan D, Pichoud C, Berby F, Stuyver L, et al. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. HEPATOLOGY 2000; 32: 10781088.
  • 14
    Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125: 17141722.
  • 15
    Chen R, Edwards R, Shaw T, Colledge D, Delaney IV WE, Isom H, et al. Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro. HEPATOLOGY 2003; 37: 2735.
  • 16
    Durantel D, Carrouee-Durantel S, Werle-Lapostolle B, Brunelle MN, Pichoud C, Trepo C, et al. A new strategy for studying in vitro the drug susceptibility of clinical isolates of human hepatitis B virus. HEPATOLOGY 2004; 40: 855864.
  • 17
    Delaney IV WE, Yang H, Westland CE, Das K, Arnold E, Gibbs CS, et al. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol 2003; 77: 1183311841.
  • 18
    Gonzales MJ, Wu TD, Taylor J, Belitskaya I, Kantor R, Israelski D, et al. Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors. AIDS 2003; 17: 791799.
  • 19
    Stuyver LJ, Locarnini SA, Lok A, Richman DD, Carman WF, Dienstag JL, et al. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. HEPATOLOGY 2001; 33: 751757.
  • 20
    Hong SP, Kim NK, Hwang SG, Chung HJ, Kim S, Han JH, et al. Detection of hepatitis B virus YMDD variants using mass spectrometric analysis of oligonucleotide fragments. J Hepatol 2004; 40: 837844.
  • 21
    Kim HS, Han KH, Ahn SH, Kim EO, Chang HY, Moon MS, et al. Evaluation of methods for monitoring drug resistance in chronic hepatitis B patients during lamivudine therapy based on mass spectrometry and reverse hybridization. Antivir Ther 2005; 10: 441449.
  • 22
    Allen MI, Gauthier J, DesLauriers M, Bourne EJ, Carrick KM, Baldanti F, et al. Two sensitive PCR-based methods for detection of hepatitis B virus variants associated with reduced susceptibility to lamivudine. J Clin Microbiol 1999; 37: 33383347.
  • 23
    Stuyver L, Van Geyt C, De Gendt S, Van Reybroeck G, Zoulim F, Leroux-Roels G, Rossau R. Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy. Journal of Clinical Microbiology 2000; 38: 702707.
  • 24
    Lok AS, Zoulim F, Locarnini S, Mangia A, Niro G, Decraemer H, et al. Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay. J Clin Microbiol 2002; 40: 37293734.
  • 25
    Hussain M, Fung S, Libbrecht E, Sablon E, Cursaro C, Andreone P, et al. Sensitive line probe assay that simultaneously detects mutations conveying resistance to lamivudine and adefovir. J Clin Microbiol 2006; 44: 10941097.
  • 26
    Tran N, Berne R, Chann R, Gauthier M, Martin D, Armand MA, et al. European multicenter evaluation of high-density DNA probe arrays for detection of hepatitis B virus resistance mutations and identification of genotypes. J Clin Microbiol 2006; 44: 27922800.
  • 27
    Palmer S, Wiegand A, Maldarelli F, Bazmi H, Mican J, Polis M, et al. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol. 2003; 41: 45314536.
  • 28
    Palmer S, Kearney M, Maldarelli F, Halvas EK, Bixby CJ, Bazmi H, et al. Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J Clin Microbiol 2005; 43: 406413.
  • 29
    Zoulim F. In vitro models for studying hepatitis B virus drug resistance. Semin Liver Dis 2006; 26: 171180.
  • 30
    Seifer M, Hamatake R, Bifano M, Standring DN. Generation of replication-competent hepatitis B virus nucleocapsids in insect cells. J Virol 1998; 72: 27652776.
  • 31
    Seifer M, Hamatake RK, Colonno RJ, Standring DN. In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir. Antimicrob Agents Chemother 1998; 42: 32003208.
  • 32
    Jacquard AC, Brunelle MN, Pichoud C, Durantel D, Carrouee-Durantel S, Trepo C, et al. In vitro characterization of the anti-hepatitis B virus activity and cross-resistance profile of 2′,3′-dideoxy-3′-fluoroguanosine. Antimicrob Agents Chemother 2006; 50: 955961.
  • 33
    Zoulim F, Seeger C. Reverse transcription in hepatitis B viruses is primed by a tyrosine residue of the polymerase. J Virol 1994; 68: 613.
  • 34
    Delaney WET, Edwards R, Colledge D, Shaw T, Torresi J, Miller TG, et al. Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus. Antimicrob Agents Chemother 2001; 45: 17051713.
  • 35
    Ladner SK, Otto MJ, Barker CS, Zaifert K, Wang GH, Guo JT, et al. Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication. Antimicrob Agents Chemother 1997; 41: 17151720.
  • 36
    Yang H, Qi X, Sabogal A, Miller M, Xiong S, Delaney WET. Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir Ther 2005; 10: 625633.
  • 37
    Yuen LK, Ayres A, Littlejohn M, Colledge D, Edgely A, Maskill WJ, et al. SEQHEPB: A sequence analysis program and relational database system for chronic hepatitis B. Antiviral Res 2006.
  • 38
    Bartholomeusz A, Tehan BG, Chalmers DK. Comparisons of the HBV and HIV polymerase, and antiviral resistance mutations. Antivir Ther 2004; 9: 149160.
  • 39
    Villeneuve JP, Durantel D, Durantel S, Westland C, Xiong S, Brosgart CL, et al. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol 2003; 39: 10851089.
  • 40
    Lai CL, Gane E, Liaw YF, Thongsawat S, Wang Y, Chen Y, et al. Telbivudine (LDT) Vs. Lamivudine for Chronic Hepatitis B: First - year results from the international phase III globe trial [Abstract]. HEPATOLOGY 2005; 42(Suppl): 748A.
  • 41
    Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, et al. Identification and characterisation of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. HEPATOLOGY 1998; 27: 16701677.
  • 42
    Ling R, Mutimer D, Ahmed M, Boxall EH, Elias E, Dusheiko GM, et al. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. HEPATOLOGY 1996; 24: 711713.
  • 43
    Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DL. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. HEPATOLOGY 1996; 24: 714717.
  • 44
    Yeh CT, Chien RN, Chu CM, Liaw YF. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. HEPATOLOGY 2000; 31: 13181326.
  • 45
    Yatsuji H, Noguchi C, Hiraga N, Mori N, Tsuge M, Imamura M, et al. Emergence of a novel lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif. Antimicrob Agents Chemother 2006; 50: 38673874.
  • 46
    Lacombe K, Ollivet A, Gozlan J, Durantel S, Tran N, Girard PM, et al. A novel hepatitis B virus mutation with resistance to adefovir but not to tenofovir in an HIV-hepatitis B viurs-co-infected patient. AIDS 2006; 20: 13.
  • 47
    Tenney DJ, Levine SM, Rose RE, Walsh AW, Weinheimer SP, Discotto L, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother 2004; 48: 34983507.
  • 48
    Brunelle MN, Jacquard AC, Pichoud C, Durantel D, Carrouee-Durantel S, Villeneuve JP, et al. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. HEPATOLOGY 2005; 41: 13911398.
  • 49
    Lim SG, Ng TM, Kung N, Krastev Z, Volfova M, Husa P, et al. A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. Arch Intern Med 2006; 166: 4956.
  • 50
    Seigneres B, Pichoud C, Martin P, Furman P, Trepo C, Zoulim F. Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses. HEPATOLOGY 2002; 36: 710722.
  • 51
    Lai CL, Leung NW, Teo EK, Tong M, Wong F, Hann HW, et al. Phase Iib Extended-Treatment Trial of Telbivudine (LdT) Vs Lamivudine Bs combination treatment in Hepatitis B patients: Two Year Results [Abstract]. J Gastroenterol 2005; 128(Suppl 2): A692.
  • 52
    Ladner S, Miller T, Otto M, King R. The hepatitis B virus M539V polymerase variation responsible for 3TC resistance also confers cross-resistance to other nucleoside analogues. Antivir Chem Chemother 1998; 9: 6572.
  • 53
    Chin R, Shaw T, Torresi J, Sozzi V, Trautwein C, Bock T, et al. In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2′-fluoro-5-methyl-beta-L-arabinofuranosyluracil. Antimicrob Agents Chemother 2001; 45: 24952501.
  • 54
    Angus P, Vaughan R, Xiong S, Yang H, Delaney W, Gibbs C, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003; 125: 292297.
  • 55
    Fung SK, Andreone P, Han SH, Rajender Reddy K, Regev A, Keeffe EB, et al. Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J Hepatol 2005; 43: 937943.
  • 56
    Villet S, Pichoud C, Villeneuve J-P, Trepo C, Zoulim F. Selection of a multiple drug resistant hepatitis B virus strain in a liver transplanted patient. Gastroenterology 2006; 131: 12531261.
  • 57
    Fung SK, Chae HB, Fontana RJ, Conjeevaram H, Marrero J, Oberhelman K, et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 2006; 44: 283290.
  • 58
    Sheldon J, Camino N, Rodes B, Bartholomeusz A, Kuiper M, Tacke F, et al. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther 2005; 10: 727734.
  • 59
    Delaney IV WE, Ray AS, Yang H, Qi X, Xiong S, Zhu Y, et al. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother 2006; 50: 24712477.
  • 60
    Yim HJ, Hussain M, Liu Y, Wong SN, Fung S, Lok A. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. HEPATOLOGY 2006; 44: 703712.
  • 61
    Villet S, Ollivet A, Pichoud C, Barraud L, Villeneuve JP, Trepo C, et al. Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. J Hepatol 2007; 46: 531538.
  • 62
    Colonno RJ, Rose R, Baldick CJ, Levine S, Pokornowski K, Yu CF, et al. Entecavir resistance is rare in nucleoside naïve patients with hepatitis B. HEPATOLOGY 2006; 44: 16561665.
  • 63
    Lampertico P, Vigano M, Manenti E, Iavarone M, Lunghi G, Colombo M. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developin genotypic resistance to lamivudine. HEPATOLOGY 2005; 42: 14141419.
  • 64
    Peters MG, Hann H, Martin P, Heathcote EJ, Buggisch P, Rubin R, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004; 126: 91101.
  • 65
    Snow A, Thibault V, Qi X, Zhu Y, Westland C, Arterburn S, et al. Combination of Adefovir Dipivoxil (ADV) and Lamivudine (LAM) prevented emergence of ADV resistance mutations in chronic hepatitis B (CHB) patients with LAM-resistant HBV. Gastroenterology 2005; 128: M945.
  • 66
    van Bommel F, Wunsche T, Mauss S, Reinke P, Bergk A, Schurmann D, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. HEPATOLOGY 2004; 40: 14211425.
  • 67
    Kuo A, Dienstag JL, Chung RT. Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B. Clin Gastroenterol Hepatol 2004; 2: 266272.
  • 68
    Chang T, Chish R, Hadziyannis S, Cianciara J, Rizzetto M, Schiff E, et al. A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. Gastroenterology 2005; 129: 11981209.
  • 69
    van Bömmel S, Zöllner B, Sarrazin C, Spengler U, Huppe D, Möller B, et al. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. HEPATOLOGY 2006.
  • 70
    Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 26822695.
  • 71
    Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 12061217.
  • 72
    Sung JJ Y LJ, Zeuzem S, Chow WC, Heathcote E, Perrillo R, Brosgart C, et al. A randomized double-blind phase II study of lamivudine compared to lamivudine plus adefovir dipivoxil for treatment naïve patients with chronic hepatitis B: week 52 analysis [Abstract]. J Hepatol 2003: 25.
  • 73
    Ono SK, Kato N, Shiratori Y, Carrilho FJ, Omata M. Novel nucleoside analogue MCC-478 (LY582563) is effective against wild-type or lamivudine-resistant hepatitis B virus. Antimicrob Agents Chemother 2002; 46: 26022605.
  • 74
    Sozzi T, Edwards R, Shaw T, Xiong S, Borroto-Esoda K, Locarnini S. antiviral cross-resistance between clinically important hbv mutants: phoenotypic testing using the recombinant HBV-Baculovirus Assay System. Global Antiviral J 2005; 1(Suppl 2): 7980.
  • 75
    Dienstag JL, Schiff E, Wright TL, Perrillo R, Hann HW, Goodman Z, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341: 12561263.
  • 76
    Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. [see comments]. N Engl J Med 1998; 339: 6168.
  • 77
    Schalm S, Heathcote J, Cianciara J, Farrell G, Sherman M, Willems B, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000; 46: 562568.
  • 78
    Westland C, Yang H, Delaney IV WE, Gibbs C, Miller M, Wulfsohn M, et al. Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B. HEPATOLOGY 2003; 38: 96103.
  • 79
    Hadziyannis S, Tassopoulos N, Chang T, Heathcote J, Kitis G, Rizzetto M, et al. Long-term adefovir dipivoxil treatment induces regression of liver fibrosis in patients with hbeag-negative chronic hepatitis b: results after 5 years of therapy [Abstract]. HEPATOLOGY 2005; 42(Suppl): 754A.
  • 80
    Lee Y, Suh D, Lim Y, Jung S, Kim K, Lee H, et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. HEPATOLOGY 2006; 43: 13851391.
  • 81
    Colonno R, Rose F, CJ B. High barrier to resistance results in no emergence of entecavir resistance in nucloside-naive subjects during the first two years of therapy [Abstract 490]. J Hepatol 2006; 44(Suppl 1): S182.
  • 82
    Lai C, Gane E, Liaw Y-F, Thongawat S, Wang Y, Heathcote E, et al. Telbivudine (LDT) vs. lamivudine for chronic hepatitis B: first-year results from the International Phase III Globe Trial [Abstract]. HEPATOLOGY 2005; 42(Suppl): 748A.